Systemic lupus erythematosus (SLE)is a chronic autoimmune inflammatory disease of unknown actiology characterized by the presence of several autoanti-bodies and by the anatomical and functional damage of multiple organs. B cells play a central role in the pathogenesis of SLE. Little is known about the frequency of the different B cell subsets in the peripheral blood of SLE patients and whether alteration of these subsets might relate to discase onset and progression. Standard therapeutic strategies. commonly using corticosteroids and immunosuppressive drugs such as azathioprine (AZA), cyclophosphamide (CyC) or methotrexate (MTX),ain at the reduction of discase activity and improvement of the patient's general conditions. Recently, the advances in antibody technology and identification of factors and pathways initiating and maintaining autoimmune disorders allowed the generation of a variety of novel molecules: humanized monoclonal anti-bodies, fusion proteins with antagonistic function and peptibodies,the so called biologic drugs. These molecules are designed to target different B cell subsets and or signalling pathways involved in B-cell activation and in the inflammatory cascade,thus hopefully sparing patients from the side effects duc to generalized immunosuppression.

                                                                                                         [Autoimmun Rev.2007:7(2):143-148]

參考譯文

系統(tǒng)性紅斑狼瘡(SLE)是一種慢性炎癥性自身免疫疾病，其病因未明，以自身抗體的出現(xiàn)和多器官結(jié)構(gòu)和功能的損害為特征。其中B細胞在SLE的發(fā)病機制中起重要作用。而SLE患者外周血中B細胞亞型的出現(xiàn)頻率以及這些亞型與疾病發(fā)生發(fā)展的相關(guān)性并不太清楚。傳統(tǒng)的治療方案包括應(yīng)用皮質(zhì)激素和免疫抑制藥如硫唑嘌吟(AZA)、環(huán)磷酰胺(CyC)、甲氨蝶吟(MTX)，其目的在于控制疾病的活動性，改善患者的一般狀況。最近,隨著抗體技術(shù)的進步以及對引起和維持自身免疫疾病的因子和路徑的認識日漸清晰，許多新藥物應(yīng)運而生，包括人化單克隆抗體、具有拮抗功能的融合蛋白和所謂的“生物制劑”。這些藥物意在針對不同的B細胞亞型和(或)B細胞活化和炎癥級聯(lián)反應(yīng)中的不同的信號傳導途徑，因此有望減少因全身免疫抑制而產(chǎn)生的不良反應(yīng)。

責任編輯：admin